Open AccessManagement of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
Author(s) -
Christian Leporini,
Francesca Saullo,
Gianfranco Filippelli,
Antonio Sorrentino,
Maria De Lucia,
Gino Perri,
Gaetana La Gattuta,
Stefania Infusino,
Rosa Toscano,
G. Dima,
Virginia Olivito,
Laura Paletta,
Ugo Bottoni,
Giovambattista De Sarro
Publication year - 2013
Publication title -
journal of pharmacology and pharmacotherapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.301
H-Index - 34
eISSN - 0976-5018
pISSN - 0976-500X
DOI - 10.4103/0976-500x.120966
Subject(s) - panitumumab , cetuximab , medicine , rash , epidermal growth factor receptor , egfr inhibitors , dermatology , colorectal cancer , oncology , pharmacology , cancer
The epidermal growth factor receptor inhibitors (EGFRIs), cetuximab and panitumumab, represent an effective treatment option for patients affected by metastatic colorectal cancer (mCRC); furthermore, they are relatively devoid of systemic toxicities, which are commonly observed with standard cytotoxic chemotherapy. However, the majority of patients treated with these monoclonal antibodies (mAbs), will experience dermatologic toxicities, most notably the papulopustular skin rash, which can impact quality-of-life and affect adherence to therapy. This paper reviews the most recent practices in the management of skin rash related to anti-epidermal growth factor receptor (EGFR) mAbs, cetuximab and panitumumab, in the treatment of mCRC.